CombinatoRx to Present Data for Oncology Programs at American Association for Cancer Research Meeting
15 4월 2010 - 9:00PM
Business Wire
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that
preclinical data on its discovery of novel synergistic drug
combinations for the treatment of cancer will be highlighted at the
101st Annual meeting of the American Association for Cancer
Research 2010, April 17-21, in Washington, DC. These preclinical
studies reinforce the rationale for investigation of A2A and β2AR
agonists in the treatment of multiple myeloma and other B-cell
malignancies and highlight the power of the CombinatoRx combination
high throughput screening (cHTS™) technology to interrogate
combination activity across large panels of cancer cells to
identify novel mechanisms for therapeutic application.
Poster Presentation:
- Abstract #5509: Wednesday, April
21, 2010, 8:00 AM - 11:00 AM, “Identification of synergistic drugs
using combination high-throughput screening,” Rickles, et.al.,
Exhibit Hall A-C, Poster Section 25, , Poster Board 29.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates
with a focus on the treatment of pain and inflammation. The company
applies its combination drug discovery capabilities and its
selective ion-channel modulation platform to generate innovative
therapeutics. To learn more about CombinatoRx, please visit
www.combinatorx.com.
Forward-Looking Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
concerning CombinatoRx, the CombinatoRx cHTS drug discovery
technology, and the business plans of CombinatoRx. These
forward-looking statements about future expectations, plans,
objectives and prospects of CombinatoRx may be identified by words
like "believe," "expect," "may," "will," "should," "seek," or
“could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the
unproven nature of the CombinatoRx cHTS drug discovery technology,
the Company's ability to obtain additional financing or funding for
its research and development and those other risks that can be
found in the "Risk Factors" section of the Company’s annual report
on Form 10-K on file with the Securities and Exchange Commission
and the other reports that CombinatoRx periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those CombinatoRx contemplated by these
forward-looking statements. These forward looking statements
reflect management’s current views and CombinatoRx does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
(c) 2010 CombinatoRx, Incorporated. All rights reserved.
Combinatorx (NASDAQ:CRXX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Combinatorx (NASDAQ:CRXX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Combinatorx, Incorporated - Common (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More CombinatoRx, Incorporated News Articles